title: Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis.
authors: *Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario Gregorio Marañón, Madrid, Spain †Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain ‡Unidad de Hepatología, Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, Spain §Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain ‖Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
authors: Matilde
authors: M
authors: Sánchez-Conde
authors: Leire
authors: L
authors: Pérez-Latorre
authors: Diego
authors: D
authors: Rincón
authors: Pilar
authors: P
authors: Miralles
authors: María-Vega
authors: MV
authors: Catalina
authors: Juan C
authors: JC
authors: López
authors: Rafael
authors: R
authors: Bañares
authors: Juan
authors: J
authors: Berenguer
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications / Q000209:etiology*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D017082:Portal Pressure / Q000502:physiology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a